The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder

Phase 1

Completed

• Conditions: Overactive Bladder

• Registration Number: NCT00553657
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial assessment of efficacy of compounds being developed for Overactive Bladder.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08
• Study First Submitted: 2007-11-02
• Study First Submitted QC: 2007-11-02
• Study First Posted: 2007-11-04
• Primary Completion: 2008-01
• Study Completion: 2008-01
• Status Verified: 2010-10
• Disposition First Submitted: 2010-10-13
• Disposition First Submitted QC: 2010-10-13
• Last Update Submitted: 2010-10-13
• Disposition First Posted: 2010-10-26
• Last Update Posted: 2010-10-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 55

Inclusion Criteria

• Eligible participants will be females who are 18 years of age or older, with Overactive Bladder as evidenced by daily episodes of urgency without incontinence, which may be associated with frequency or nocturia but without bladder pain. At screening, eligible patients must report frequency, defined as at least 8 micturitions per 24 hour period.
• Eligible patients must have signed the informed consent and must meet all inclusion and exclusion criteria as determined during the screening visit.

Exclusion Criteria

• Any abnormality identified on the screening examination or any other medical condition or circumstance making the patient unsuitable for participation in the study based on the Investigator's and Medical Monitor's assessment
• Any contraindication to Detrol LA or other anti-muscarinic medications
• Inability to consume 10 cc/kg of fluid within 30 minutes
• Regular alcohol consumption averaging ³7 drinks/week for women (1 drink = 100mL of wine or 285mL of beer or 30mL of hard liquor)
• Positive urine drug or alcohol at screening at screening
• Average blood pressure measurements systolic ≥140 or diastolic ≥90 at screening at screening
• QTcB value ≥ 450 msec at screening
• Poorly-controlled diabetes mellitus or hypertension, as evidenced by a change in medication within the 2 months prior to initiation of the study
• History of urinary retention or gastric retention
• Known history of narrow-angle glaucoma
• History of QT prolongation
• Known reduction in hepatic or renal function
• Concomitant Use of loop diuretics (eg. Furosemide)
• Concomitant use of a medication that is a potent inhibitor of CYP3A4
• Class IA or Class III antiarrhythmic medications
• Patient is unable and/or unwilling to adhere to Lifestyle Guidelines
• For women of child bearing potential, a positive serum β-hCG at screening or pre-dose, or an unwillingness to agree to adequate contraception from the time of screening until the completion of the study:
• Positive for hepatitis C antibody, hepatitis B surface antigen or HIV at screening.
• Presence of urinary tract infection within 4 weeks of screening.
• Post-void residual of >150 mL (bladder ultrasound).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Variability of change from baseline in mean volume per void measured on 3 consecutive days.	3 consecutive days

Secondary Outcome Measures

Name	Time	Method
Mean change from baseline in volume voided per void. Percent and actual change from baseline in maximum volume voided, number of micturitions, number of incontinence episodes, number of urgency episodes, and time to first void on 3 consecutive days.	3 consecutive days

Trial Locations

Locations (1)

GSK Investigational Site; 🇦🇺 Randwick, Sydney, New South Wales, Australia